✦ LIBER ✦

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule

✍ Scribed by Xiao-Du Guo; Nancy Harold; M. Wasif Saif; Barbara Schuler; Eva Szabo; J. Michael Hamilton; Brian P. Monahan; Mary G. Quinn; Janet Cliatt; Diana Nguyen; Frank Grollman; Rebecca R. Thomas; Elizabeth A. McQuigan; Richard Wilson; Chis H. Takimoto; Jean L. Grem

Publisher: Springer
Year: 2003
Tongue: English
Weight: 214 KB
Volume: 52
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-003-0613-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and pharmacodynamic eff

Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion

✍ Jean L. Grem; Mary Quinn; Abdel Ismail; Chris H. Takimoto; Richard Lush; David J 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 243 KB

Effect of tofisopam on the single-oral-d

Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam

✍ Sándor Drabant; Mária Tóth; Andrea Bereczki; Judit Bajnógel; Judit Tömlö; Imre K 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 55 KB

Indobufen (K 3920), a new inhibitor of p

Indobufen (K 3920), a new inhibitor of platelet aggregation: Effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man

✍ V. Tamassia; G. Corvi; L. M. Fuccella; E. Moro; G. Tosolini; E. Tremoli 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 480 KB

Treatment of advanced adenocarcinomas of

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.)

✍ Vittorio Gebbia; Evaristo Majello; Antonio Testa; Giuseppe Pezzella; Serravezza 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 787 KB

## BACKGROUND. To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase I1 trial has been performed by the Southern Italy Oncology Group with the aim of e